{
  "schemaVersion": "2.0",
  "lastUpdated": "2025-01-09",
  
  "substances": [
    {
      "id": "ketamine_001",
      "name": "Ketamine",
      "aliases": ["Special K", "Vitamin K", "K", "kit-kat", "keets", "super acid", "super k", "jet"],
      "classification": {
        "primary": "dissociative_anesthetic",
        "secondary": ["NMDA_receptor_antagonist", "non_classical_psychedelic"],
        "mechanism": "noncompetitive_NMDA_receptor_antagonist",
        "receptorAffinity": {
          "NMDA": "high_antagonist",
          "opioid": "moderate",
          "monoamine_transporters": "moderate"
        }
      },
      "developmentHistory": {
        "era": "1960s",
        "purpose": "Alternative to phencyclidine (PCP)",
        "initialUse": "anesthetic"
      },
      "prevalenceData": {
        "lifetimeUse": [
          {
            "value": 2.3,
            "unit": "million",
            "population": "US teens and adults",
            "year": 2006,
            "context": "lifetime use",
            "citations": ["liu_2016"]
          },
          {
            "value": 5.93,
            "unit": "percent",
            "population": "Global Drug Survey respondents",
            "year": 2018,
            "context": "lifetime use",
            "citations": ["barrios_2024"]
          }
        ],
        "emergencyRoomVisits": {
          "rate": 0.6,
          "unit": "percent",
          "year": 2020,
          "context": "Of all users seeking emergency care",
          "citations": ["canady_2023"]
        },
        "adverseEvents": {
          "rate": 0.1,
          "unit": "percent",
          "context": "Past-year users requiring EMT",
          "total_events": 120,
          "total_users": 4477,
          "year": 2024,
          "citations": ["barrios_2024"]
        },
        "dependence": {
          "rate": 8.55,
          "unit": "percent",
          "context": "Past-year users meeting dependence criteria",
          "year": 2024,
          "citations": ["barrios_2024"]
        }
      },
      "dosing": {
        "anesthetic": {
          "min": 2,
          "max": 10,
          "unit": "mg/kg",
          "route": "IV or IM",
          "purpose": "surgical anesthesia"
        },
        "subanesthetic_therapeutic": {
          "typical": 0.5,
          "unit": "mg/kg",
          "route": "IV",
          "duration": "40 minutes infusion",
          "purpose": "depression treatment",
          "citations": ["riva_posse_2018", "raja_2024"]
        },
        "recreational_low": {
          "min": 0.1,
          "max": 0.6,
          "unit": "mg/kg",
          "effects": ["mild relaxation", "dissociation", "euphoria", "time/space/body distortions"],
          "state": "K-land"
        },
        "recreational_high": {
          "description": "Higher doses leading to K-hole",
          "effects": ["profound dissociation", "out-of-body experiences"],
          "experience": "can be pleasurable or terrifying"
        },
        "clinical_range": {
          "min": 0.5,
          "max": 1.5,
          "unit": "mg/kg",
          "route": "IV or IM",
          "citations": ["kelly_2023"]
        },
        "weightDependence": true,
        "notes": "Effects highly dose-dependent; no standardized dosing protocols exist"
      },
      "pharmacokinetics": {
        "absorption": {
          "routes": ["oral", "intranasal", "sublingual", "intramuscular", "intravenous"],
          "bioavailability": {
            "oral": "moderate",
            "intranasal": "moderate_to_high",
            "IV": "100%"
          }
        },
        "onset": {
          "IV": "1-5 minutes",
          "IM": "5-15 minutes",
          "intranasal": "5-10 minutes",
          "oral": "15-30 minutes"
        },
        "peak": {
          "IV": "5-10 minutes",
          "other_routes": "variable"
        },
        "duration": {
          "short_acting": "1-2 hours primary effects",
          "aftereffects": "several hours"
        },
        "metabolism": "primarily hepatic",
        "elimination": "renal",
        "formulation": "hydrochloride salt, often racemic mixture"
      },
      "subjectiveEffects": {
        "dissociative": [
          "bodily transcendence",
          "detachment from self or world",
          "altered proprioception",
          "feelings of unity",
          "consciousness expansion"
        ],
        "perceptual": [
          "visual distortions",
          "auditory changes",
          "time distortion",
          "space distortion",
          "body perception changes"
        ],
        "emotional": [
          "euphoria",
          "empathy",
          "transcendence",
          "anxiety (in some)"
        ],
        "dose_dependent_states": {
          "low_dose": "mild relaxation and dissociation",
          "k_land": "moderate dissociative state",
          "k_hole": "profound dissociation, potentially distressing or transcendent"
        }
      },
      "toleranceDevelopment": {
        "rate": "moderate_to_rapid",
        "mechanism": "regular use leads to tolerance",
        "consequence": "higher doses needed for effects",
        "risk": "increased adverse effects and dependence potential",
        "citations": ["ingrosso_2024", "bonnet_2015"]
      },
      "addictionPotential": "moderate_to_high",
      "physiologicalDependence": {
        "prevalence": "associated with prolonged and heavy use",
        "symptoms": ["cravings", "psychological distress"],
        "citations": ["barrios_2024", "baumeister_2015", "lacroix_2024"]
      },
      "psychologicalDependence": {
        "prevalence": "moderate",
        "reinforcingProperties": "present due to euphoric and dissociative effects",
        "citations": ["liu_2016"]
      }
    }
  ],

  "riskFactors": [
    {
      "id": "rf_ketamine_dosage_001",
      "name": "Lack of Standardized Dosing",
      "category": "dosing",
      "severity": "high",
      "description": "Absence of standardized dosing protocols leads to inconsistencies",
      "specificRisks": [
        {
          "risk": "unintentional_adverse_effects",
          "severity": "moderate_to_high",
          "mechanism": "difficulty defining low/medium/high doses"
        },
        {
          "risk": "psychotic_symptoms",
          "severity": "high",
          "trigger": "doses exceeding therapeutic range",
          "populations": "individuals with psychosis vulnerability"
        },
        {
          "risk": "k_hole_distress",
          "severity": "moderate_to_high",
          "description": "profound dissociation intensely disturbing for some"
        }
      ],
      "citations": ["cornfield_2024", "baumeister_2015"]
    },
    {
      "id": "rf_ketamine_cognitive_001",
      "name": "Cognitive Impairment Risk",
      "category": "psychological",
      "subcategory": "cognitive",
      "severity": "moderate_to_high",
      "timeframe": "chronic use",
      "description": "Long-term cognitive deficits particularly in memory",
      "evidence": {
        "ketamine_dependent": "worse performance and slower task completion",
        "domains_affected": ["memory", "verbal learning", "spatial memory"],
        "preservation": ["attentional processes may be spared", "spatial memory may be spared"]
      },
      "functionalImpairment": true,
      "citations": ["baumeister_2015", "gomez_escolar_2024", "liu_2016", "maxwell_2005"]
    },
    {
      "id": "rf_ketamine_personality_001",
      "name": "Pre-existing Personality Disorders",
      "category": "psychiatric",
      "severity": "high",
      "description": "Individuals with personality disorders at elevated risk",
      "specificRisks": {
        "negativeResponse": {
          "probability": 31,
          "unit": "percent"
        },
        "adversePsychologicalResponse": {
          "riskMultiplier": 4,
          "description": "Greater than four-fold elevated risk"
        }
      },
      "citations": ["collins_2024", "marrocu_nd"]
    },
    {
      "id": "rf_ketamine_gi_001",
      "name": "Gastrointestinal Complications",
      "category": "physiological",
      "subcategory": "gastrointestinal",
      "severity": "moderate",
      "description": "K-cramps and abdominal pain",
      "prevalence": {
        "emergency_admission": 21,
        "unit": "percent",
        "context": "patients admitted to ER for ketamine use"
      },
      "riskFactors": ["frequent use", "high doses"],
      "citations": ["baumeister_2015"]
    },
    {
      "id": "rf_ketamine_urinary_001",
      "name": "Urinary Tract Damage",
      "category": "physiological",
      "subcategory": "urological",
      "severity": "high",
      "description": "Chronic use linked to ulcerative cystitis and bladder dysfunction",
      "specificConditions": [
        {
          "condition": "ulcerative_cystitis",
          "commonName": "ketamine bladder",
          "symptoms": ["painful urination", "frequent urination", "hematuria"],
          "longTermEffect": "bladder dysfunction"
        },
        {
          "condition": "ketamine_associated_uropathy",
          "effects": ["renal function decline"]
        },
        {
          "condition": "other_urological",
          "manifestations": ["haemorrhagic cystitis", "hydronephrosis", "contracted bladder", "ureteral stenosis"]
        }
      ],
      "prevalence": {
        "value": 25,
        "operator": ">",
        "unit": "percent",
        "context": "regular users experiencing urinary symptoms"
      },
      "doseResponse": "severity linked to frequency and dosage",
      "citations": ["baumeister_2015", "lacroix_2024", "ou_2020"]
    },
    {
      "id": "rf_ketamine_polydrug_001",
      "name": "Polysubstance Use with Ketamine",
      "category": "behavioral",
      "subcategory": "substance_use",
      "severity": "high",
      "description": "Ketamine frequently combined with other substances",
      "commonCombinations": [
        {
          "substances": ["ketamine", "MDMA"],
          "prevalence": "common"
        },
        {
          "substances": ["ketamine", "cannabis"],
          "prevalence": "common"
        },
        {
          "substances": ["ketamine", "cocaine"],
          "prevalence": "common",
          "risk": "lethal effects increased"
        },
        {
          "substances": ["ketamine", "methamphetamine"],
          "risk": "lethal effects increased"
        },
        {
          "substances": ["ketamine", "alcohol"],
          "risk": "increased sedation and respiratory depression"
        },
        {
          "substances": ["ketamine", "benzodiazepines"],
          "risk": "increased sedation and respiratory depression"
        },
        {
          "substances": ["ketamine", "CNS_depressants"],
          "risk": "potentially fatal respiratory depression"
        }
      ],
      "citations": ["barrios_2024", "guo_2022"]
    },
    {
      "id": "rf_ketamine_roa_intranasal_001",
      "name": "Intranasal Route Risks",
      "category": "administration",
      "route": "intranasal",
      "specificRisks": [
        {
          "risk": "misuse_and_abuse",
          "severity": "moderate_to_high",
          "context": "heightened in unsupervised settings"
        },
        {
          "risk": "traffic_accidents",
          "mechanism": "dissociation and impaired coordination"
        },
        {
          "risk": "elevated_blood_pressure",
          "consequences": ["heart failure risk", "myocardial infarction risk"]
        }
      ],
      "citations": ["sapkota_2021"]
    },
    {
      "id": "rf_ketamine_roa_sublingual_001",
      "name": "Sublingual Route Risks",
      "category": "administration",
      "route": "sublingual",
      "specificRisks": [
        {
          "risk": "difficulty_staying_present",
          "mechanism": "high doses shift toward mystical experiences",
          "therapeuticImplication": "may interfere with therapy engagement"
        }
      ],
      "citations": ["cornfield_2024"]
    },
    {
      "id": "rf_ketamine_contamination_001",
      "name": "Contamination and Purity Issues",
      "category": "quality",
      "severity": "high",
      "description": "Illicit ketamine purity cannot be guaranteed",
      "risks": [
        "unknown substances present",
        "variable potency",
        "dangerous adulterants"
      ],
      "longTermRisks": {
        "cognitiveImpairment": "may be linked to contaminated supplies",
        "urinaryTractDamage": "may be linked to contaminated supplies"
      },
      "harmReduction": ["drug testing kits", "trusted sources"],
      "limitations": "testing kits cannot provide comprehensive analysis",
      "citations": ["lacroix_2024", "glynos_2023"]
    }
  ],

  "medicalConditions": [
    {
      "id": "cond_ketamine_hypertension_001",
      "name": "Untreated Hypertension",
      "category": "cardiovascular",
      "icd10": "I10",
      "contraindicationType": "absolute",
      "severity": "critical",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "mechanism": "Ketamine elevates blood pressure and heart rate",
          "specificRisks": [
            {
              "risk": "hypertensive_crisis",
              "severity": "critical"
            },
            {
              "risk": "cardiovascular_event",
              "severity": "critical"
            }
          ],
          "contraindicationType": "absolute",
          "citations": ["gomez_escolar_2024", "bennett_2023"]
        }
      ]
    },
    {
      "id": "cond_ketamine_cvd_001",
      "name": "Cardiovascular Disease",
      "category": "cardiovascular",
      "icd10": "I00-I99",
      "contraindicationType": "absolute",
      "severity": "critical",
      "description": "Active or poorly managed cardiovascular conditions",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "mechanism": "Increased blood pressure and heart rate",
          "physiologicalEffects": {
            "bloodPressure": {
              "effect": "elevation",
              "severity": "moderate",
              "note": "small changes generally well-tolerated",
              "exception": "higher peaks in hypertensive patients"
            },
            "heartRate": {
              "effect": "elevation",
              "severity": "moderate"
            },
            "catecholamines": {
              "mechanism": "decreased reuptake"
            }
          },
          "contraindicationType": "absolute",
          "citations": ["gomez_escolar_2024", "bennett_2023", "riva_posse_2018"]
        }
      ]
    },
    {
      "id": "cond_ketamine_psychosis_001",
      "name": "Active Psychotic Disorder",
      "category": "psychiatric",
      "icd10": "F20-F29",
      "contraindicationType": "absolute",
      "severity": "critical",
      "description": "Current psychotic symptoms including schizophrenia",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "mechanism": "Psychotomimetic properties can exacerbate symptoms",
          "specificRisks": [
            "worsening_hallucinations",
            "increased_delusions",
            "thought_disorganization"
          ],
          "contraindicationType": "absolute",
          "citations": ["baumeister_2015", "collins_2024"]
        }
      ]
    },
    {
      "id": "cond_ketamine_pregnancy_001",
      "name": "Pregnancy and Breastfeeding",
      "category": "reproductive",
      "icd10": "Z33",
      "contraindicationType": "relative",
      "severity": "high",
      "description": "Limited safety data for fetal/infant exposure",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "evidenceLevel": "limited",
          "recommendation": "avoid use due to unknown risks",
          "citations": ["pacilio_2024", "wolfson_2022"]
        }
      ]
    },
    {
      "id": "cond_ketamine_substance_abuse_001",
      "name": "History of Substance Abuse",
      "category": "psychiatric",
      "subcategory": "addiction",
      "icd10": "F10-F19",
      "contraindicationType": "relative",
      "severity": "moderate_to_high",
      "description": "Previous substance use disorder",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "specificRisks": [
            {
              "risk": "dependence_development",
              "vulnerability": "increased"
            },
            {
              "risk": "cravings",
              "vulnerability": "increased"
            }
          ],
          "requiredPrecautions": [
            "thorough screening",
            "close monitoring",
            "enhanced support"
          ],
          "citations": ["baumeister_2015"]
        }
      ]
    },
    {
      "id": "cond_ketamine_liver_001",
      "name": "Liver Disease",
      "category": "hepatic",
      "icd10": "K70-K77",
      "contraindicationType": "relative",
      "severity": "high",
      "description": "Severe liver impairment",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "mechanism": "Ketamine primarily metabolized by liver",
          "consequence": "drug accumulation and increased adverse event risk",
          "requiredPrecautions": [
            "dose adjustment",
            "monitoring liver function",
            "careful risk-benefit assessment"
          ],
          "citations": ["wong_2014"]
        }
      ]
    },
    {
      "id": "cond_ketamine_kidney_001",
      "name": "Kidney Disease",
      "category": "renal",
      "icd10": "N00-N29",
      "contraindicationType": "relative",
      "severity": "high",
      "description": "Pre-existing renal impairment",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "bidirectionalRisk": true,
          "mechanisms": [
            "Ketamine can cause urinary tract complications",
            "Pre-existing kidney disease may be exacerbated",
            "Risk of further renal damage"
          ],
          "specificCondition": "ketamine_associated_uropathy",
          "citations": ["ou_2020"]
        }
      ]
    },
    {
      "id": "cond_ketamine_glaucoma_001",
      "name": "Glaucoma",
      "category": "ophthalmologic",
      "icd10": "H40",
      "contraindicationType": "relative",
      "severity": "moderate",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "mechanism": "Increases intraocular pressure",
          "consequence": "worsening of glaucoma symptoms",
          "citations": ["joaquin_2019"]
        }
      ]
    },
    {
      "id": "cond_ketamine_anxiety_001",
      "name": "Anxiety Disorders",
      "category": "psychiatric",
      "icd10": "F40-F48",
      "contraindicationType": "relative",
      "severity": "moderate",
      "nuance": "complex - may help some forms but worsen others",
      "substanceRisks": [
        {
          "substanceId": "ketamine_001",
          "paradoxicalEffect": true,
          "positiveEvidence": "shown promise treating some anxiety forms",
          "negativeRisk": "may trigger heightened anxiety or panic in some individuals",
          "recommendation": "careful screening and monitoring required",
          "citations": ["niesters_2013"]
        }
      ]
    }
  ],

  "adverseEvents": [
    {
      "id": "ae_ketamine_dissociation_001",
      "name": "Dissociative Symptoms",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "mild_to_severe",
      "description": "Defining effects - detachment from body and surroundings",
      "manifestations": [
        {
          "symptom": "depersonalization",
          "intensity": "mild_to_profound"
        },
        {
          "symptom": "derealization",
          "intensity": "mild_to_profound"
        },
        {
          "symptom": "perceptual_distortions",
          "intensity": "mild"
        },
        {
          "symptom": "k_hole",
          "intensity": "profound",
          "description": "complete sensory detachment",
          "variability": "disturbing for some, transcendent for others"
        }
      ],
      "prevalence": "most common acute effect",
      "clinicalSignificance": "expected effect but can be disturbing",
      "citations": ["baumeister_2015", "cornfield_2024"]
    },
    {
      "id": "ae_ketamine_neuropsych_001",
      "name": "Acute Neuropsychiatric Effects",
      "category": "psychological",
      "timeframe": "acute",
      "severity": "moderate_to_high",
      "symptoms": [
        "anxiety",
        "agitation",
        "confusion",
        "psychotic_like_symptoms"
      ],
      "riskFactors": [
        "higher doses",
        "pre-existing psychosis vulnerability"
      ],
      "citations": ["breeksema_2022", "kelly_2023", "collins_2024"]
    },
    {
      "id": "ae_ketamine_cardiovascular_001",
      "name": "Acute Cardiovascular Effects",
      "category": "physiological",
      "subcategory": "cardiovascular",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "effects": {
        "bloodPressure": {
          "change": "increase",
          "typical": "transient and well-tolerated",
          "higherRisk": "hypertensive patients",
          "mechanism": "decreased catecholamine reuptake"
        },
        "heartRate": {
          "change": "increase",
          "typical": "transient"
        }
      },
      "resolution": "resolves with drug metabolism",
      "riskPopulations": ["pre-existing cardiovascular conditions"],
      "citations": ["breeksema_2022", "gomez_escolar_2024", "riva_posse_2018"]
    },
    {
      "id": "ae_ketamine_gi_acute_001",
      "name": "Acute Gastrointestinal Distress",
      "category": "physiological",
      "subcategory": "gastrointestinal",
      "timeframe": "acute",
      "severity": "mild_to_moderate",
      "symptoms": [
        "nausea",
        "vomiting"
      ],
      "prevalence": "relatively common",
      "doseResponse": "especially at higher doses",
      "mechanism": "effects on GI tract",
      "citations": ["baumeister_2015", "kelly_2023"]
    },
    {
      "id": "ae_ketamine_respiratory_001",
      "name": "Respiratory Depression",
      "category": "physiological",
      "subcategory": "respiratory",
      "timeframe": "acute",
      "severity": "moderate_to_severe",
      "triggers": [
        "high doses",
        "rapid IV administration"
      ],
      "requirement": "careful monitoring",
      "intervention": "supportive measures may be needed",
      "setting": "clinical settings with monitoring capacity",
      "citations": ["kelly_2023"]
    },
    {
      "id": "ae_ketamine_emt_001",
      "name": "Emergency Medical Treatment Events",
      "category": "acute_care",
      "timeframe": "acute",
      "prevalence": {
        "rate": 0.1,
        "unit": "percent",
        "denominator": "past-year users",
        "adverseEventsReported": 120,
        "totalUsers": 4477,
        "proportionSeekingEMT": 28.89,
        "unit_proportion": "percent"
      },
      "note": "relatively rare despite common use",
      "citations": ["barrios_2024"]
    },
    {
      "id": "ae_ketamine_cognitive_long_001",
      "name": "Long-term Cognitive Impairment",
      "category": "psychological",
      "subcategory": "cognitive",
      "timeframe": "long_term",
      "severity": "moderate_to_high",
      "description": "Persistent cognitive decline with chronic use",
      "affectedDomains": [
        {
          "domain": "memory",
          "severity": "significant",
          "specifics": ["verbal learning", "spatial memory"]
        },
        {
          "domain": "executive_function",
          "severity": "moderate"
        },
        {
          "domain": "processing_speed",
          "severity": "moderate",
          "manifestation": "require more time for cognitive tasks"
        }
      ],
      "sparedDomains": [
        "attentional processes (may be spared)",
        "spatial memory (may be spared)"
      ],
      "correlates": "correlated with estimated lifetime ketamine use",
      "functionalImpairment": true,
      "citations": ["lacroix_2024", "baumeister_2015", "hase_2022", "liu_2016", "maxwell_2005"]
    },
    {
      "id": "ae_ketamine_mental_health_001",
      "name": "Mental Health Deterioration",
      "category": "psychological",
      "timeframe": "long_term",
      "severity": "moderate_to_high",
      "manifestations": [
        {
          "symptom": "depressive_symptoms",
          "note": "can increase despite antidepressant effects"
        },
        {
          "symptom": "schizophrenia_like_positive_symptoms",
          "examples": ["hallucinations", "delusions"]
        },
        {
          "symptom": "schizophrenia_like_negative_symptoms",
          "examples": ["detachment", "flat affect"]
        },
        {
          "symptom": "increased_anxiety",
          "context": "particularly when hungover"
        },
        {
          "symptom": "mania",
          "context": "associated with intoxication"
        },
        {
          "symptom": "paranoia",
          "context": "associated with intoxication"
        }
      ],
      "psychopathologicalSequelae": "prolonged use may contribute to or worsen mental health problems",
      "vulnerablePopulations": "those with pre-existing vulnerabilities",
      "citations": ["lie_2016", "carhart_harris_2010", "baumeister_2015", "bremler_2023"]
    },
    {
      "id": "ae_ketamine_dependence_001",
      "name": "Ketamine Dependence",
      "category": "addiction",
      "timeframe": "long_term",
      "severity": "high",
      "description": "Cravings and tolerance with prolonged heavy use",
      "prevalence": {
        "dependenceCriteria": {
          "value": 8.55,
          "unit": "percent",
          "population": "past-year users",
          "year": 2024
        },
        "alternateEstimate": {
          "value": 17,
          "unit": "percent",
          "population": "ketamine users"
        }
      },
      "characteristics": [
        "cravings",
        "tolerance development",
        "withdrawal symptoms",
        "psychological distress on cessation"
      ],
      "concerningContext": "especially with oral/intranasal formulations for depression",
      "linkedRisk": "association with other drug dependence",
      "helpSeeking": {
        "note": "majority meeting criteria did not want help to use less",
        "implication": "complex relationship with perceived problem"
      },
      "citations": ["barrios_2024", "baumeister_2015", "lacroix_2024", "ingrosso_2024"]
    },
    {
      "id": "ae_ketamine_tolerance_001",
      "name": "Tolerance Development",
      "category": "pharmacological",
      "timeframe": "develops_with_regular_use",
      "severity": "moderate",
      "description": "Higher doses required for desired effects",
      "consequence": [
        "increased risk of adverse effects",
        "potential contribution to dependence"
      ],
      "citations": ["ingrosso_2024", "bonnet_2015"]
    },
    {
      "id": "ae_ketamine_urinary_chronic_001",
      "name": "Chronic Urinary Tract Damage",
      "category": "physiological",
      "subcategory": "urological",
      "timeframe": "long_term",
      "severity": "high",
      "description": "Ketamine bladder and related urological complications",
      "conditions": [
        {
          "condition": "ulcerative_cystitis",
          "commonName": "ketamine bladder",
          "symptoms": [
            "painful urination",
            "frequent urination",
            "hematuria (blood in urine)"
          ],
          "longTermConsequence": "bladder dysfunction"
        },
        {
          "condition": "haemorrhagic_cystitis"
        },
        {
          "condition": "hydronephrosis"
        },
        {
          "condition": "contracted_bladder"
        },
        {
          "condition": "ureteral_stenosis"
        }
      ],
      "prevalence": {
        "value": 25,
        "operator": ">",
        "unit": "percent",
        "population": "regular ketamine users",
        "symptomType": "urinary symptoms"
      },
      "severityFactors": [
        "frequency of use",
        "dosage"
      ],
      "functionalImpairment": "can cause debilitating symptoms",
      "citations": ["baumeister_2015", "lacroix_2024"]
    },
    {
      "id": "ae_ketamine_neurotoxicity_001",
      "name": "Neurotoxicity",
      "category": "physiological",
      "subcategory": "neurological",
      "timeframe": "long_term",
      "severity": "high",
      "evidence": {
        "animal_studies": {
          "findings": "kidney and bladder damage at human-equivalent dosing",
          "subjects": "rodents"
        },
        "human_studies": {
          "findings": "grey matter depletion in certain brain regions",
          "implication": "potential structural brain changes"
        }
      },
      "citations": ["baumeister_2015", "gomez_escolar_2024"]
    },
    {
      "id": "ae_ketamine_gi_chronic_001",
      "name": "Chronic Gastrointestinal Toxicity",
      "category": "physiological",
      "subcategory": "gastrointestinal",
      "timeframe": "long_term",
      "severity": "moderate",
      "symptoms": [
        "K-cramps",
        "vomiting",
        "dysphagia (difficulty swallowing)"
      ],
      "association": "chronic ketamine use"
    }
  ],

  "therapeuticAlliance": [
    {
      "id": "alliance_ketamine_quality_001",
      "name": "Therapeutic Alliance in Ketamine Treatment",
      "category": "relational",
      "description": "Quality of relationship between therapist and patient in ketamine-assisted therapy",
      "importance": "critical",
      "impact": "Influences treatment outcomes and safety",
      "ketamineSpecificConsiderations": [
        {
          "consideration": "dissociative_state_navigation",
          "description": "Therapist must support patient through dissociative experiences",
          "challenge": "maintaining connection during profound dissociation"
        },
        {
          "consideration": "dose_related_challenges",
          "description": "Higher doses shift toward mystical experiences",
          "therapeuticTension": "balance between therapeutic engagement and transcendent experience"
        }
      ],
      "components": [
        {
          "component": "safety",
          "description": "Physical and emotional safety during dissociative states"
        },
        {
          "component": "trust",
          "description": "Essential given vulnerability during dissociation"
        },
        {
          "component": "presence",
          "description": "Grounding presence despite patient's altered state"
        }
      ],
      "citations": ["cornfield_2024"]
    }
  ],

  "preparationPractices": [
    {
      "id": "prep_ketamine_screening_001",
      "name": "Ketamine-Specific Screening",
      "category": "assessment",
      "timing": "pre_session",
      "components": [
        {
          "area": "cardiovascular_assessment",
          "tools": ["blood pressure monitoring", "ECG if indicated", "cardiovascular history"],
          "focus": [
            "hypertension status",
            "cardiac arrhythmias",
            "history of heart disease"
          ],
          "rationale": "ketamine elevates BP and HR"
        },
        {
          "area": "urological_history",
          "tools": ["medical history", "symptom review"],
          "focus": [
            "pre-existing urinary conditions",
            "kidney function",
            "bladder issues"
          ],
          "rationale": "risk of urinary tract damage"
        },
        {
          "area": "hepatic_function",
          "tools": ["liver function tests", "medical history"],
          "focus": [
            "liver disease",
            "metabolic capacity"
          ],
          "rationale": "ketamine primarily metabolized by liver"
        },
        {
          "area": "substance_use_history",
          "tools": ["detailed substance use interview"],
          "focus": [
            "history of dependence",
            "current substance use",
            "risk of ketamine dependence"
          ],
          "rationale": "dependence potential concerns"
        }
      ],
      "exclusionCriteria": [
        "untreated hypertension",
        "active cardiovascular disease",
        "active psychotic disorder",
        "severe liver impairment",
        "severe kidney disease",
        "pregnancy",
        "glaucoma"
      ],
      "relativeContraindications": [
        "history of substance abuse",
        "controlled cardiovascular conditions",
        "anxiety disorders",
        "liver disease (mild-moderate)",
        "kidney disease (mild-moderate)"
      ]
    },
    {
      "id": "prep_ketamine_education_001",
      "name": "Ketamine-Specific Education",
      "category": "education",
      "timing": "pre_session",
      "content": [
        {
          "topic": "dissociative_effects",
          "details": [
            "nature of dissociation",
            "K-land vs K-hole states",
            "variability of experience",
            "both distressing and transcendent possibilities"
          ]
        },
        {
          "topic": "dose_response",
          "details": [
            "highly dose-dependent effects",
            "importance of accurate dosing",
            "lack of standardized protocols"
          ]
        },
        {
          "topic": "physical_effects",
          "details": [
            "cardiovascular changes",
            "possible nausea",
            "urinary considerations",
            "GI effects"
          ]
        },
        {
          "topic": "dependence_risk",
          "details": [
            "potential for tolerance",
            "cravings development",
            "importance of adherence to protocol"
          ]
        }
      ]
    }
  ],

  "integrationPractices": [
    {
      "id": "int_ketamine_dissociation_001",
      "name": "Dissociative Experience Integration",
      "category": "psychological",
      "timing": "post_session",
      "ketamineSpecific": true,
      "description": "Processing profound dissociative and out-of-body experiences",
      "challenges": [
        "ineffability of dissociative states",
        "integration of ego dissolution",
        "making sense of K-hole experiences"
      ],
      "approaches": [
        {
          "approach": "narrative_construction",
          "description": "helping patient create coherent narrative of dissociative experience"
        },
        {
          "approach": "meaning_making",
          "description": "exploring personal significance of ego transcendence"
        },
        {
          "approach": "grounding_practices",
          "description": "re-establishing connection to body and identity"
        }
      ]
    },
    {
      "id": "int_ketamine_frequency_001",
      "name": "Treatment Frequency Monitoring",
      "category": "safety",
      "timing": "ongoing",
      "ketamineSpecific": true,
      "description": "Monitoring for signs of tolerance and dependence",
      "components": [
        "regular assessment of dose effectiveness",
        "screening for cravings",
        "monitoring urinary symptoms",
        "cognitive function checks"
      ],
      "interventions": [
        "dose adjustment",
        "treatment interval modification",
        "dependence risk management"
      ]
    }
  ],

  "emergencyResponseProtocols": [
    {
      "id": "emergency_ketamine_cardiovascular_001",
      "name": "Cardiovascular Event Management",
      "category": "medical_emergency",
      "priority": "high",
      "ketamineSpecific": true,
      "triggers": [
        "severe hypertension",
        "chest pain",
        "arrhythmia",
        "signs of cardiac distress"
      ],
      "interventions": [
        {
          "intervention": "vital_sign_monitoring",
          "frequency": "continuous",
          "parameters": ["blood pressure", "heart rate", "ECG if available"]
        },
        {
          "intervention": "medical_consultation",
          "urgency": "immediate",
          "indication": "any significant cardiovascular symptoms"
        },
        {
          "intervention": "antihypertensive_consideration",
          "condition": "severe hypertension",
          "note": "consult medical professional"
        },
        {
          "intervention": "emergency_services",
          "indication": "chest pain, severe symptoms, or suspected MI"
        }
      ]
    },
    {
      "id": "emergency_ketamine_dissociation_001",
      "name": "Severe Dissociation Management",
      "category": "psychological",
      "priority": "high",
      "ketamineSpecific": true,
      "description": "Managing distressing K-hole or profound dissociative states",
      "interventions": [
        {
          "intervention": "environmental_management",
          "actions": [
            "ensure physical safety",
            "remove hazards",
            "prevent wandering or injury"
          ]
        },
        {
          "intervention": "verbal_reassurance",
          "technique": "calm, steady voice reminding of safety and temporary nature"
        },
        {
          "intervention": "grounding_techniques",
          "examples": ["gentle touch (with consent)", "auditory anchors"],
          "limitation": "may be less effective during profound dissociation"
        },
        {
          "intervention": "time_and_presence",
          "description": "allowing experience to resolve naturally with supportive presence"
        },
        {
          "intervention": "benzodiazepines",
          "indication": "if reassurance insufficient and severe distress persists",
          "status": "second-line"
        }
      ]
    },
    {
      "id": "emergency_ketamine_respiratory_001",
      "name": "Respiratory Depression Protocol",
      "category": "medical_emergency",
      "priority": "critical",
      "ketamineSpecific": true,
      "triggers": [
        "decreased respiratory rate",
        "shallow breathing",
        "cyanosis",
        "oxygen desaturation"
      ],
      "interventions": [
        {
          "intervention": "airway_management",
          "priority": "immediate",
          "actions": ["ensure patent airway", "positioning"]
        },
        {
          "intervention": "oxygen_administration",
          "indication": "any respiratory compromise"
        },
        {
          "intervention": "assisted_ventilation",
          "indication": "severe respiratory depression",
          "requirement": "trained personnel and equipment"
        },
        {
          "intervention": "emergency_medical_services",
          "urgency": "immediate",
          "indication": "any significant respiratory depression"
        }
      ],
      "prevention": [
        "avoid high doses",
        "avoid rapid IV administration",
        "screening for respiratory conditions",
        "avoiding CNS depressant combinations"
      ]
    }
  ],

  "assessmentTools": [
    {
      "id": "tool_ketamine_urinary_001",
      "name": "Urinary Symptom Assessment",
      "purpose": "Monitor for ketamine-associated uropathy",
      "type": "ketamine_specific",
      "domains": [
        "urinary frequency",
        "urgency",
        "pain on urination",
        "hematuria",
        "bladder capacity"
      ],
      "frequency": "regular monitoring for chronic users",
      "importance": "early detection of urinary tract damage"
    },
    {
      "id": "tool_ketamine_cognitive_001",
      "name": "Cognitive Function Battery",
      "purpose": "Monitor for cognitive decline with chronic use",
      "type": "neuropsychological",
      "domains": [
        "verbal learning",
        "spatial memory",
        "processing speed",
        "executive function",
        "attention"
      ],
      "frequency": "baseline and periodic reassessment",
      "importance": "detect early cognitive impairment"
    },
    {
      "id": "tool_ketamine_dependence_001",
      "name": "Dependence Risk Screening",
      "purpose": "Assess for signs of ketamine dependence",
      "type": "behavioral",
      "domains": [
        "cravings",
        "tolerance",
        "difficulty controlling use",
        "withdrawal symptoms",
        "continued use despite problems"
      ],
      "frequency": "ongoing monitoring",
      "importance": "early intervention for dependence"
    }
  ],

  "complexInteractions": [
    {
      "id": "interact_ketamine_cns_001",
      "factors": [
        {"type": "substance", "id": "ketamine_001"},
        {"type": "substance_class", "id": "cns_depressants"},
        {"type": "setting", "id": "unsupervised"}
      ],
      "riskMultiplier": "very_high",
      "specificOutcome": "Severe sedation and potentially fatal respiratory depression",
      "mechanism": [
        "Additive CNS depression",
        "Respiratory depression potentiation",
        "Reduced protective reflexes"
      ],
      "specificCombinations": [
        {"with": "alcohol", "risk": "very_high"},
        {"with": "benzodiazepines", "risk": "very_high"},
        {"with": "opioids", "risk": "critical"}
      ],
      "prevention": [
        "Screen for concurrent substance use",
        "Education about dangerous combinations",
        "Supervised administration only"
      ],
      "evidenceQuality": "strong",
      "citations": ["guo_2022"]
    },
    {
      "id": "interact_ketamine_stimulant_001",
      "factors": [
        {"type": "substance", "id": "ketamine_001"},
        {"type": "substance_class", "id": "psychostimulants"}
      ],
      "riskMultiplier": "high",
      "specificOutcome": "Increased lethal effects of stimulants",
      "mechanism": "Ketamine increases lethal effects of cocaine and methamphetamine",
      "specificCombinations": [
        {"with": "cocaine", "risk": "high", "prevalence": "common"},
        {"with": "methamphetamine", "risk": "high"}
      ],
      "evidenceQuality": "moderate",
      "citations": ["barrios_2024"]
    },
    {
      "id": "interact_ketamine_cardiovascular_001",
      "factors": [
        {"type": "substance", "id": "ketamine_001"},
        {"type": "medical_condition", "id": "cond_ketamine_hypertension_001"},
        {"type": "dose", "level": "any"}
      ],
      "riskMultiplier": "critical",
      "specificOutcome": "Hypertensive crisis or cardiovascular event",
      "mechanism": "Ketamine's BP elevation superimposed on existing hypertension",
      "contraindicationType": "absolute",
      "evidenceQuality": "strong",
      "citations": ["gomez_escolar_2024", "bennett_2023"]
    },
    {
      "id": "interact_ketamine_chronic_high_dose_001",
      "factors": [
        {"type": "substance", "id": "ketamine_001"},
        {"type": "pattern", "id": "chronic_high_dose_use"},
        {"type": "duration", "timeframe": "prolonged"}
      ],
      "riskMultiplier": "very_high",
      "specificOutcomes": [
        "Ketamine bladder syndrome",
        "Cognitive impairment",
        "Dependence"
      ],
      "doseResponseRelationship": "severity increases with frequency and dosage",
      "reversibility": {
        "cognitive": "partially reversible with cessation",
        "urological": "may have lasting damage",
        "dependence": "requires treatment"
      },
      "evidenceQuality": "strong",
      "citations": ["baumeister_2015", "lacroix_2024"]
    }
  ],

  "contaminationQualityFactors": [
    {
      "id": "contam_ketamine_purity_001",
      "name": "Ketamine Purity Variability",
      "category": "quality",
      "severity": "high",
      "description": "Illicit ketamine has unverifiable purity and potency",
      "risks": [
        "unknown substance presence",
        "variable potency",
        "accidental overdose",
        "underdosing",
        "unexpected effects"
      ],
      "concerningEvidence": {
        "longTermEffects": "chronic effects may be linked to contaminated supplies rather than pure drug",
        "affectedOutcomes": ["cognitive impairment", "urinary tract damage"]
      },
      "harmReduction": [
        "drug testing kits (limited effectiveness)",
        "trusted sources",
        "test dosing",
        "pharmaceutical-grade when possible"
      ],
      "citations": ["lacroix_2024", "glynos_2023"]
    },
    {
      "id": "contam_ketamine_source_001",
      "name": "Unregulated Source Risks",
      "category": "sourcing",
      "severity": "high",
      "description": "Obtaining ketamine from illicit markets",
      "risks": [
        "no quality control",
        "unknown composition",
        "dangerous adulterants",
        "exposure to criminal activity",
        "violence risk",
        "legal consequences"
      ],
      "prevention": [
        "use only in regulated clinical settings when possible",
        "harm reduction services",
        "drug checking programs"
      ],
      "citations": ["glynos_2023"]
    }
  ],

  "legalSocioeconomicFactors": [
    {
      "id": "legal_ketamine_status_001",
      "name": "Controlled Substance Status",
      "category": "legal",
      "description": "Ketamine scheduling varies by jurisdiction",
      "impacts": [
        {
          "impact": "limited_recreational_access",
          "severity": "high",
          "consequence": "drives use to unregulated markets"
        },
        {
          "impact": "medical_availability",
          "severity": "moderate",
          "note": "available for medical use but restricted"
        },
        {
          "impact": "research_barriers",
          "severity": "moderate",
          "consequence": "limits safety and efficacy research"
        }
      ]
    },
    {
      "id": "socioeconomic_ketamine_therapy_cost_001",
      "name": "High Cost of Ketamine Therapy",
      "category": "socioeconomic",
      "description": "Ketamine-assisted therapy expensive and often not covered",
      "barriers": [
        {
          "barrier": "treatment_cost",
          "impact": "only wealthy can access safe therapeutic use"
        },
        {
          "barrier": "insurance_coverage",
          "status": "limited",
          "impact": "out-of-pocket costs prohibitive"
        }
      ],
      "consequence": "wealth-based treatment divide, poor relegated to unsafe recreational use",
      "citations": ["barber_2024"]
    },
    {
      "id": "socioeconomic_ketamine_rave_culture_001",
      "name": "Association with Rave Culture",
      "category": "cultural",
      "description": "Recreational ketamine use linked to party settings",
      "risks": [
        "polydrug use in party settings",
        "lack of medical supervision",
        "unsafe environments",
        "hot environments (cardiovascular stress)",
        "dehydration risks"
      ],
      "prevalenceNote": "increasing globally, evidenced by wastewater analysis",
      "citations": ["barrios_2024"]
    }
  ],

  "groupDynamicsFactors": [
    {
      "id": "group_ketamine_party_001",
      "name": "Party and Festival Settings",
      "category": "recreational_setting",
      "description": "Ketamine use in uncontrolled party environments",
      "risks": [
        "lack of medical supervision",
        "polydrug use encouragement",
        "unsafe physical environments",
        "peer pressure for higher doses",
        "inability to seek help due to stigma or legal concerns"
      ],
      "prevalenceContext": "common in rave and electronic music culture"
    }
  ],

  "culturalSpiritualFactors": [
    {
      "id": "cultural_ketamine_western_001",
      "name": "Western Medicalization Context",
      "category": "cultural",
      "description": "Ketamine used primarily in medical/therapeutic context in West",
      "considerations": [
        "pharmaceutical framing",
        "clinical setting emphasis",
        "depression treatment focus",
        "less spiritual/ceremonial context than classical psychedelics"
      ],
      "contrast": "differs from classical psychedelics with indigenous histories"
    },
    {
      "id": "spiritual_ketamine_experiences_001",
      "name": "Mystical and Transcendent Experiences",
      "category": "spiritual",
      "description": "Ketamine can produce profound spiritual experiences",
      "manifestations": [
        "ego dissolution",
        "unity consciousness",
        "out-of-body experiences",
        "transcendent states",
        "near-death-like experiences"
      ],
      "therapeuticImplications": {
        "positive": "may contribute to therapeutic benefit",
        "negative": "can interfere with staying present in therapy",
        "doseRelated": "higher doses more likely to produce mystical experiences"
      },
      "citations": ["cornfield_2024"]
    }
  ],

  "doseResponseCurves": [
    {
      "substanceId": "ketamine_001",
      "outcome": "dissociative_state",
      "relationship": "positive_correlation",
      "dataPoints": [
        {
          "dose": "0.1-0.6",
          "unit": "mg/kg",
          "state": "K-land",
          "effects": ["mild relaxation", "dissociation", "euphoria"]
        },
        {
          "dose": ">0.6",
          "unit": "mg/kg",
          "state": "K-hole",
          "effects": ["profound dissociation", "complete sensory detachment"]
        }
      ],
      "interpretation": "Clear dose-dependent progression of dissociative states",
      "evidenceQuality": "strong",
      "citations": ["liu_2016", "petersen_2020"]
    },
    {
      "substanceId": "ketamine_001",
      "outcome": "mystical_experience",
      "relationship": "positive_correlation",
      "note": "Higher sublingual doses shift toward mystical/transcendent experiences",
      "therapeuticTension": "balance between engagement and transcendence",
      "citations": ["cornfield_2024"]
    },
    {
      "substanceId": "ketamine_001",
      "outcome": "adverse_effects",
      "relationship": "positive_correlation",
      "effects": [
        "psychotic symptoms increase at high doses",
        "cardiovascular effects more pronounced at higher doses",
        "nausea more common at higher doses"
      ],
      "evidenceQuality": "strong"
    }
  ],

  "metadata": {
    "documentSource": "Ketamine Literature Review Extract",
    "extractDate": "2025-01-09",
    "primaryResearchTypes": [
      "clinical_trials",
      "observational_studies",
      "case_reports",
      "epidemiological_surveys",
      "animal_studies"
    ],
    "geographicScope": "Global with emphasis on North America and Europe",
    "lastLiteratureSearch": "2024",
    "qualityAssessment": "Comprehensive but with specific limitations",
    "knownLimitations": [
      "Limited long-term follow-up studies",
      "Contamination may confound chronic effect studies",
      "Lack of standardized dosing protocols",
      "Variable quality of recreational use data",
      "Underrepresentation of therapeutic versus recreational contexts",
      "Limited diversity in clinical research populations",
      "Difficulty separating ketamine effects from polydrug effects in recreational contexts"
    ],
    "ketamineSpecificNotes": [
      "Classification as psychedelic is debated in literature",
      "Unique dissociative mechanism distinct from classical psychedelics",
      "Well-established medical use creates different risk profile than purely recreational substances",
      "Dependence and chronic effects more prominent concern than with classical psychedelics",
      "Urological complications are unique and concerning long-term risk"
    ],
    "citationCount": "approximately 100+ unique sources in extract",
    "crossReferencesWithPsilocybinSchema": [
      "General psychedelic risk factors apply",
      "Set and setting principles similar",
      "Integration practices overlap",
      "Therapeutic alliance considerations similar but with dissociation-specific adaptations"
    ]
  }
}